ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study

Meng, Qianhao; Zhao, Jian; Yu, Yuanyuan; Wang, Ke; Ren, Jing; Xu, Chang; Wang, Yusheng*; Wang, Guangyu*哈尔滨医科大学; 中国医学科学院
BMC CANCER2023-2-27DOI: 10.1186/s12885-023-10640-9
1被引5阅读
引用收藏
分享

摘要

BackgroundPatients with V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E-mutated advanced colorectal cancer (CRC) have a poor prognosis, and treatment options that can improve outcome are still under investigation. The purpose of this study was to discuss the differences of overall survival (OS) and progression-free survival (PFS) between patients with BRAF V600E-mutated advanced CRC who were treated with chemotherapy alone and chemotherapy combined with targeted therapy in advanced first-line therapy.MethodsGrouping of 61 patients according to first-line treatment regimen (chemotherapy alone/chemotherapy combined with bevacizumab). Kaplan-Meier method and log-rank test were used to compare OS and PFS. Cox proportional hazards regression model was used to measure the risk of first-line medication therapies while correcting for confounding factors that may affect PFS and OS.ResultsThere was no significant difference in OS between patients treated with chemotherapy alone and those treated with chemotherapy combined with bevacizumab (P = 0.93; HR, 1.027; 95% CI, 0.555-1.901). Likewise, there was no significant difference in PFS between the two groups (P = 0.29; HR, 0.734; 95% CI, 0.413-1.304). Subgroup analysis showed that OS and PFS of different treatment regimens were not significantly different among subgroups. Multivariate analysis suggested that surgical treatment of primary tumor (P = 0.001; HR, 0.326; 95% CI, 0.169-0.631) and presence of liver metastasis (P = 0.009; HR, 2.399; 95% CI, 1.242-4.635) may serve as independent prognostic indicators in patients with BRAF-mutated advanced CRC. Surgical treatment of the primary tumor (P = 0.041; HR, 0.523; 95% CI, 0.280-0.974) was significantly associated with PFS too.ConclusionFor patients with BRAF V600E-mutated advanced CRC, chemotherapy alone did not differ significantly in OS and PFS compared with chemotherapy + bevacizumab for advanced first-line therapy. Chemotherapy combined with targeted therapy did not render a survival benefit to these patients, demonstrating that the importance of developing new treatment options for this population.

学科与关键词

关键词
Advanced colorectal cancerBRAF V600E mutationOverall survivalProgression-free survival
相关
加载中…
  • First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
    Liu, Shousheng; Jiang, Chang; Yang, Lin; Huang, Jinsheng; Peng, Roujun; Wang, Xiaopai; He, Wenzhuo; Bai, Long; Zhou, Yixin; Zhang, Bei*; Xia, Liangping*Scientific Reports, 2020, 10(1): 12336.被引 7
  • The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses
    Chen, Yungchang; Sun, Hao; Deng, Yanhong; Ma, Yutong; Huang, He; Liu, Yang; Zhang, Yaru; Zhang, Hongyu; Ye, Sheng; Mingyan, E.; Guo, Hongqiang; Wu, Mengmeng; Wu, Chunman; Pu, Xingxiang; Chen, Xinggui; Liang, Chaoyong; Ou, Qiuxiang; Weng, Huawei; Wu, Xue; Shao, Yang; Gu, Anxin*; Lin, Tongyu*Biomarker Research, 2023, 11(1): 11.被引 3
  • A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ? Bevacizumab versus FOLFOX ? Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
    Wang, Feng; He, Ming -Ming; Xiao, Jian; Zhang, Yan-Qiao; Yuan, Xiang-Lin; Fang, Wei-Jia; Zhang, Yan; Wang, Wei; Hu, Xiao-Hua; Ma, Zhi-Gang; Yao, Yi-Chen; Zhuang, Zhi-Xiang; Zhou, Fu-Xiang; Ying, Jie-Er; Yuan, Ying; Zou, Qing-Feng; Guo, Zeng-Qing; Wu, Xiang-Yuan; Jin, Ying; Mai, Zong-Jiong; Wang, Zhi-Qiang; Qiu, Hong; Guo, Ying; Shi, Si -Mei; Chen, Shuang-Zhen; Luo, Hui-Yan; Zhang, Dong-Sheng; Wang, Feng-Hua*; Li, Yu-Hong; Xu, Rui-Hua*Clinical Cancer Research, 2022, 28(19): 4232-4239.被引 6
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC CANCER
发表日期
2023-02-27
卷期
第 23 卷, 第 1 期
页码
191
DOI
10.1186/s12885-023-10640-9
语言
ENGLISH
成果收录
SCIE

作者

  • M

    Meng, Qianhao (第一作者)

    harbin med univ

  • Z

    Zhao, Jian

    chinese acad med sci · shanxi med univ · shanxi prov canc hosp

查看全部 8 位作者收起作者
  • Y

    Yu, Yuanyuan

    harbin med univ

  • W

    Wang, Ke

    harbin med univ

  • R

    Ren, Jing

    harbin med univ

  • X

    Xu, Chang

    harbin med univ

  • W

    Wang, Yusheng (通讯)

    chinese acad med sci · shanxi med univ · shanxi prov canc hosp

  • W

    Wang, Guangyu (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417